Wisp and Vesalius Longevity Labs have partnered to launch peptides catered to women’s health needs, citing a need to close the gap between men’s and women’s innovation in the longevity space
Vesalius Longevity Labs, the company behind peptide brand Peptual, is going all-in on women’s health in a new partnership with telehealth provider Wisp. The two health tech brands are launching an exclusive range of peptide therapies designed to enhance women’s quality of life and promote longevity.
The companies are taking advantage of the profitable peptide market, which was valued at $42.1 billion in 2024 and expected to reach $117.4 billion by 2034. Vesalius has already capitalized on that growth by backing Peptual and its line of peptides and bioregulators, but now the focus is all about women’s health.
“Women make up half the population, yet they’ve been treated like an afterthought in the longevity space,” said Wisp CEO Monica Cepak.
“Our mission is to close that gap by making advanced therapeutics both accessible and affordable for women at every stage of life,” Cepak continued. “By partnering with Vesalius, we’re introducing peptides into women’s healthcare and expanding access to a powerful tool that can transform how women age.”
Vesalius and Wisp will refine Peptual’s existing line of injectables, patches, nasal sprays, oral and topical formulations to design a product portfolio — set to launch in early 2026 — aimed at specific aspects of women’s health, like fertility and menopause.
The two brands are just the latest wellness companies to make a bold investment in women’s health. Peloton recently co-launched a study on how targeted exercise may improve menopause-related symptoms, amplifying the growing trend of women’s health and midlife care in the fitness and wellness industry.
“Our product innovation team and globally recognized Scientific Advisory Board are committed to working closely with Wisp to accelerate access to safe, effective solutions,” Vesalius CEO Kevin Rabbitt said. “By combining Vesalius’ expertise in longevity science with Wisp’s leadership in women’s healthcare, we’re ushering in a new era that will meaningfully extend women’s lifespan.”
The move also comes soon after Wisp’s entrance into the longevity-focused supplement category, with the Wisp Thrive Creatine Tablets and Wisp Revive Collagen Tablets. The telehealth company currently services over 1.5 million patients across the U.S., addressing women’s health needs such as birth control, fertility, menopause and STI testing.
